Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

DNA Bacteriophages

DNA Bacteriophages

Bacteriophages, or phages, are viruses that specifically infect bacteria, utilizing their genetic material to hijack host cellular machinery for replication. DNA bacteriophages employ single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) genomes. These phages exhibit diverse replication strategies and host interactions, influencing their ecological roles and applications in biotechnology and medicine.ssDNA BacteriophagesssDNA phages, with their small genomes, utilize unique strategies to...

Cross-reactivity

Cross-reactivity

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.

NeuroImage. Clinical·2022

Same author

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.

The Lancet. Neurology·2020

Same author

Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a.

Multiple sclerosis journal - experimental, translational and clinical·2019

Same author

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Journal of neurology·2019

Same author

Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?

Multiple sclerosis journal - experimental, translational and clinical·2019

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Skin Tattooing As A Novel Approach For DNA Vaccine Delivery

Skin Tattooing As A Novel Approach For DNA Vaccine Delivery

Published on: October 18, 2012

A DNA vaccine for multiple sclerosis.

Hideki Garren¹

¹Stanford University, Department of Neurology and Neurological Sciences, Stanford, CA, USA. hgarren@stanford.edu

Expert Opinion on Biological Therapy

|September 9, 2008

Summary

A DNA vaccine for multiple sclerosis (MS) showed promising safety and efficacy in clinical trials. This antigen-specific therapy, BHT-3009, reduced brain lesions and relapses in MS patients.

Area of Science:

Neuroimmunology
Vaccine development
Autoimmune diseases

Background:

Multiple sclerosis (MS) requires safe and effective therapeutic strategies.
Antigen-specific treatments offer a promising approach to managing MS by targeting specific immune responses.
DNA vaccines represent an evolving modality for antigen-specific immunotherapy.

Purpose of the Study:

To evaluate the viability of a DNA vaccine as an antigen-specific treatment for multiple sclerosis.
To assess the safety and efficacy profile of BHT-3009, a DNA vaccine targeting myelin basic protein.

Main Methods:

Phase I and II clinical trials were conducted to assess BHT-3009.
The study focused on safety, tolerability, and immune response in MS patients.

More Related Videos

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: Jul 2, 2026

Skin Tattooing As A Novel Approach For DNA Vaccine Delivery

Skin Tattooing As A Novel Approach For DNA Vaccine Delivery

Published on: October 18, 2012

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Efficacy was measured by reduction in brain lesion activity and clinical relapses.

Main Results:

BHT-3009 was found to be safe and well-tolerated in patients with multiple sclerosis.
The vaccine successfully induced antigen-specific immune tolerance.
Significant reductions in brain lesion activity and clinical relapses were observed in patients with active disease at baseline.

Conclusions:

BHT-3009 demonstrates potential as a novel, safe, and effective antigen-specific therapy for multiple sclerosis.
This DNA vaccine may represent a breakthrough in the development of targeted treatments for MS.
Further development of BHT-3009 is warranted based on its promising clinical trial outcomes.